Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2017: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2016: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
Outline of Final Research Achievements |
We invastigated that intraocular injection of edaravone exerts neuroprotective effects in an ONI model.Sequential in vivo retinal imaging revealed that post-ONI treatment with edaravone was effective for maintaining the retinal structure. We also demonstrated that edaravone suppressed the production of ROS and stress-induced ASK1-p38 MAPK signaling, which leads to RGC survival following ONI(Akiyama et al. IOVS, 2017). We also investigated that the effect of ocular hypertension in human surgical procedure(Akiyama et al. Sci Rep, 2016). .
|